Physician profile
Deepika Devalla
NPI 1265872592
$479.30
in general payments reported to CMS, 2019-2025
11 companies · $88.16 in 2025
The $88.16 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.23 · 2020: $81.18 · 2021: $51.04 · 2022: $102 · 2023: $59.03 · 2024: $28.91 · 2025: $88.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $118.03 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $88.85 | 2021-2022 | |
| Organon LLC | $87.44 | 2024-2025 | Nexplanon, Jada System |
| Merck Sharp & Dohme LLC | $58.69 | 2019-2020 | |
| Biogen, INC. | $29.63 | 2025 | Zurzuvae |
| Cranial Technologies, INC | $25.19 | 2023 | Doc Band |
| Agile Therapeutics, INC. | $17.66 | 2023 | Twirla |
| Inari Medical, INC. | $16.18 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kci USA, INC. | $14.01 | 2022 | |
| Vifor Pharma, INC. | $11.81 | 2019 | |
| Novo Nordisk INC | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Devalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.